The US FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.

A new review and policy statement underscore the inaccuracy of sickle cell trait as a cause of death on autopsies.

The suzetrigine, which only acts on pain neurons, is the first innovation in analgesia in the last 20 years. "It stands out ...

The case-series studies identified chest pain as the most common cardiovascular symptom among long-COVID patients (22%), ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

When prescribing opioids for acute pain, physicians should be attentive to a patient’s individual risk factors, according to ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

Opioid prescriptions in the emergency department (ED) were associated with small increases in later opioid prescriptions and hospital admissions, found new research published in CMAJ (Canadian Medical ...

In the second world war, the physician Henry Beecher observed that some of his soldier patients, despite being injured on the ...

Loose Women's Andrea McLean has given a health update after 'collapsing' at home and being diagnosed with 'severe pneumonia' and 'sepsis' ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...